Our DFSP work, characterizing CDK4 as a therapeutic target in imatinib-resistant DFSP and introducing the first patient-derived representative model of FS-DFSP, has been published in the AACR journal Molecular Cancer Therapeutics. Check it out here.
Our DFSP work, characterizing CDK4 as a therapeutic target in imatinib-resistant DFSP and introducing the first patient-derived representative model of FS-DFSP, has been published in the AACR journal Molecular Cancer Therapeutics. Check it out here.
